D. Prechtel

Frequent Loss of Heterozygosity at Chromosome 13q12–13 with BRCA2 Markers in Sporadic Male Breast Cancer

H. Höfler, A. Werenskiold, G. Keller, 1998, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

C‐Met overexpression in node‐positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu

E. Lengyel, G. V. Vande Woude, N. Harbeck, 2005, International journal of cancer.

Clinical Relevance of T1-S, an Oncogene-Inducible, Secreted Glycoprotein of the Immunoglobulin Superfamily, in Node-Negative Breast Cancer

H. Höfler, N. Harbeck, A. Werenskiold, 2001, Laboratory Investigation.

Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer.

E. Lengyel, M. Schmitt, W. Kuhn, 2001, Gynecologic oncology.

Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer.

E. Lengyel, M. Schmitt, W. Kuhn, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Tumor-associated overexpression of the soluble T1-S receptor in lymph node-negative breast cancer.

H. Höfler, N. Harbeck, A. Werenskiold, 2000, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b

E. Lengyel, N. Harbeck, M. Schmitt, 2000, Oncogene.

[Quantitative determination of steroid hormone receptors in breast cancer tissue outside tumor centers].

K. Prechtel, D. Prechtel, 1993, Der Pathologe.